Samuel T Wilkinson1, Carly Kiselycznyk2, Mounira Banasr3, Ryan D Webler2, Colin Haile4, Sanjay J Mathew4. 1. Yale School of Medicine, 100 York St, STE 2J, New Haven, CT 06511, United States. Electronic address: samuel.wilkinson@yale.edu. 2. Yale School of Medicine, 100 York St, STE 2J, New Haven, CT 06511, United States. 3. Campbell Family Mental Health Research Institute of CAMH (Centre of Addiction and Mental Health), Toronto, ON, Canada. 4. Baylor College of Medicine, Houston, TX, United States; Michael E. DeBakey VA Medical Center, Houston, TX, United States.
Abstract
BACKGROUND:Serum brain-derived neurotrophic factor (BDNF) is decreased in individuals with major depressive disorder (MDD). Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties. Here we report serum (sBDNF) and plasma (pBDNF) levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in MDD. METHODS:Serum and plasma BDNF samples were drawn at baseline and weeks 6 and 8 from 55 subjects randomized to adjunctive treatment with riluzole or placebo for 8 weeks. RESULTS:Riluzole responders had lower baseline serum (19.08 ng/ml [SD 9.22] v. 28.80 ng/ml [9.63], p = 0.08) and plasma (2.72 ng/ml [1.07] v. 4.60 ng/ml [1.69], p = 0.06) BDNF compared to non-responders at a trend level. This pattern was nominally seen in placebo responders for baseline pBDNF to some degree (1.21 ng/ml [SD 1.29] v. 3.58 ng/ml [SD 1.67], p = 0.12) but not in baseline sBDNF. LIMITATIONS: A number of limitations warrant comment, including the small sample size of viable BDNF samples and the small number of riluzole responders. CONCLUSIONS: Preliminary evidence reported here suggests that lower baseline BDNF may be associated with better clinical response to riluzole.
RCT Entities:
BACKGROUND: Serum brain-derived neurotrophic factor (BDNF) is decreased in individuals with major depressive disorder (MDD). Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties. Here we report serum (sBDNF) and plasma (pBDNF) levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in MDD. METHODS: Serum and plasma BDNF samples were drawn at baseline and weeks 6 and 8 from 55 subjects randomized to adjunctive treatment with riluzole or placebo for 8 weeks. RESULTS:Riluzole responders had lower baseline serum (19.08 ng/ml [SD 9.22] v. 28.80 ng/ml [9.63], p = 0.08) and plasma (2.72 ng/ml [1.07] v. 4.60 ng/ml [1.69], p = 0.06) BDNF compared to non-responders at a trend level. This pattern was nominally seen in placebo responders for baseline pBDNF to some degree (1.21 ng/ml [SD 1.29] v. 3.58 ng/ml [SD 1.67], p = 0.12) but not in baseline sBDNF. LIMITATIONS: A number of limitations warrant comment, including the small sample size of viable BDNF samples and the small number of riluzole responders. CONCLUSIONS: Preliminary evidence reported here suggests that lower baseline BDNF may be associated with better clinical response to riluzole.
Authors: Rong-Jian Liu; Francis S Lee; Xiao-Yuan Li; Francis Bambico; Ronald S Duman; George K Aghajanian Journal: Biol Psychiatry Date: 2011-10-29 Impact factor: 13.382
Authors: M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora Journal: Mol Psychiatry Date: 2008-09-30 Impact factor: 15.992
Authors: Hitoshi Sakurai; Christina Dording; Albert Yeung; Simmie Foster; Felipe Jain; Trina Chang; Nhi-Ha Trinh; Richard Bernard; Sean Boyden; Syed Z Iqbal; Samuel T Wilkinson; Sanjay J Mathew; David Mischoulon; Maurizio Fava; Cristina Cusin Journal: J Affect Disord Date: 2019-07-02 Impact factor: 4.839
Authors: Giuliana Travassos Pires Santiago; Ana Cecília de Menezes Galvão; Raíssa Nóbrega de Almeida; Sergio Arthuro Mota-Rolim; Fernanda Palhano-Fontes; João Paulo Maia-de-Oliveira; Dráulio Barros de Araújo; Bruno Lobão-Soares; Nicole Leite Galvão-Coelho Journal: Front Behav Neurosci Date: 2020-04-28 Impact factor: 3.558